Literature DB >> 9877479

Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis.

L P Ho1, J A Innes, A P Greening.   

Abstract

Airways inflammation has been associated with increased nitric oxide (NO) in the exhaled breath. It was, therefore, questioned whether exhaled NO could act as an indicator of the severity of airways inflammation in the chronic suppurative lung diseases cystic fibrosis (CF) and bronchiectasis. NO levels in a single exhalation were measured using a chemiluminescence analyser. Thirty-six patients with CF and 16 with bronchiectasis were studied and compared with 22 normal subjects and 35 asthmatic patients. All subjects were nonsmokers and all measurements were made when patients were clinically stable. In addition, exhaled NO was measured in 10 CF patients at the time of onset of an acute infective exacerbation and followed for 7 days during the treatment of the exacerbation in eight of the 10 patients. No significant differences were found in NO levels in patients with CF or bronchiectasis compared with normals (median 4.0, 5.5 and 4.4 parts per billion (ppb), respectively), but all were lower than in asthma patients (10.4 ppb). The NO levels in the CF patients at time of exacerbation were not increased and did not change during treatment. These data show that nitric oxide levels in the exhaled breath of patients with chronic suppurative lung diseases, in contrast to asthma, are not elevated, despite the presence of substantial airways inflammation. Possible explanations include poor diffusion of nitric oxide across increased and viscous airway secretions, removal of nitric oxide by reaction with reactive oxygen species in the inflamed environment and failure of upregulation of epithelial inducible nitric oxide synthase in chronic suppurative conditions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9877479     DOI: 10.1183/09031936.98.12061290

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

1.  Increase in exhaled carbon monoxide during exacerbations of cystic fibrosis.

Authors:  J D Antuni; S A Kharitonov; D Hughes; M E Hodson; P J Barnes
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

2.  Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis.

Authors:  J C Ojoo; S A Mulrennan; J A Kastelik; A H Morice; A E Redington
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

3.  Sputum proteomics in inflammatory and suppurative respiratory diseases.

Authors:  Robert D Gray; Gordon MacGregor; Donald Noble; Margaret Imrie; Maria Dewar; A Christopher Boyd; J Alastair Innes; David J Porteous; Andrew P Greening
Journal:  Am J Respir Crit Care Med       Date:  2008-06-19       Impact factor: 21.405

4.  Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma.

Authors:  Feng-Jia Chen; Huai Liao; Xin-Yan Huang; Can-Mao Xie
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

Review 5.  Exhaled nitric oxide measurements: clinical application and interpretation.

Authors:  D R Taylor; M W Pijnenburg; A D Smith; J C De Jongste
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

6.  Stimulated nitric oxide production and arginine deficiency in children with cystic fibrosis with nutritional failure.

Authors:  Mariëlle P K J Engelen; Gulnur Com; Yvette C Luiking; Nicolaas E P Deutz
Journal:  J Pediatr       Date:  2013-02-15       Impact factor: 4.406

Review 7.  Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

Authors:  Rainer Büscher; Hartmut Grasemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-11       Impact factor: 3.000

8.  Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia.

Authors:  I Horváth; S Loukides; T Wodehouse; E Csiszér; P J Cole; S A Kharitonov; P J Barnes
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

Review 9.  The role of inhaled corticosteroids in the management of cystic fibrosis.

Authors:  Kristie R Ross; James F Chmiel; Michael W Konstan
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

10.  Exhaled nitric oxide in diagnosis and management of respiratory diseases.

Authors:  Abdullah A Abba
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.